Trial Profile

Safety and Immunogenicity of GSK's Rabies G SAM (CNE) Vaccine [GSK3903133A] in Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 3903133A (Primary) ; Rabies vaccine
Indications Rabies
Focus Adverse reactions; First in man
Sponsors GlaxoSmithKline; GSK

Most Recent Events

04 Aug 2022 Status changed from active, no longer recruiting to completed.
17 May 2021 Planned End Date changed from 18 Nov 2022 to 21 Jun 2022.
17 May 2021 Planned primary completion date changed from 10 Aug 2021 to 27 Jul 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com